{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:57:58Z","timestamp":1781143078139,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109455","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:11:59Z","timestamp":1778548319000},"page":"109455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Consensus recommendations on surveillance and survivorship for patients with unresectable\/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts"],"prefix":"10.1016","volume":"217","author":[{"given":"Jenny J.","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Clelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Navani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wheatley-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Melosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.lungcan.2026.109455_b0005","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1503\/cmaj.240095","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"CMAJ."},{"key":"10.1016\/j.lungcan.2026.109455_b0010","unstructured":"Canadian Cancer Statistics 2024. Canadian Cancer Society; 2024."},{"key":"10.1016\/j.lungcan.2026.109455_b0015","doi-asserted-by":"crossref","unstructured":"Garon EB, Hui R, Leighl NB, Patnaik A, Aggarwal C, Zhou Q, et al. 10-Year Outcomes From Clinical Trials of Pembrolizumab Monotherapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Presented at: ESMO Congress; October 17-21, 2025; Berlin, Germany. Abstract 3208P.","DOI":"10.1016\/j.annonc.2025.08.2714"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109455_b0020","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109455_b0025","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u226550%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2026.109455_b0030","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in CheckMate 9LA","volume":"208","author":"Reck","year":"2024","journal-title":"Eur J Cancer."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109455_b0035","first-page":"497","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"42","author":"Johnson","year":"2024","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109455_b0040","first-page":"45","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: 5-year outcomes from the EMPOWER-Lung 1 study","volume":"20","author":"Gogishvili","year":"2025","journal-title":"J Thorac Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109455_b0045","first-page":"123","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: 5-year outcomes from the EMPOWER-Lung 3 study","volume":"20","author":"Baramidze","year":"2025","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.lungcan.2026.109455_b0050","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109455_b0055","first-page":"1002","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Planchard","year":"2022","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109455_b0060","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs."},{"key":"10.1016\/j.lungcan.2026.109455_b0065","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND\/UCLA Appropriateness Method User\u2019s Manual. RAND Corporation; 2001."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109455_b0070","article-title":"Real-world outcomes of immunotherapy in advanced NSCLC: a community oncology network experience","volume":"3","author":"Waterhouse","year":"2022","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2026.109455_b0075","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2025."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109455_b0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of Co-occurring genomic alterations on outcomes in patients with KRAS-mutant non\u2013small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"15 suppl","key":"10.1016\/j.lungcan.2026.109455_b0085","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1200\/JCO.2021.39.15_suppl.9050","article-title":"Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapy","volume":"39","author":"Christoph","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2026.109455_b0090","article-title":"Late immune-related adverse events after at least two years of immune checkpoint inhibitor therapy: incidence and association with survival in patients with advanced NSCLC","volume":"6","author":"Elghawy","year":"2025","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2026.109455_b0095","first-page":"16","article-title":"Patient involvement in guidelines is poor five years after Institute of Medicine standards: review of guideline methodologies","volume":"3","author":"Brouwers","year":"2017","journal-title":"Res Involv Engagem."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:11:28Z","timestamp":1781140288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"alternative-id":["S0169500226005167"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109455","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus recommendations on surveillance and survivorship for patients with unresectable\/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109455"}}